Statins are associated with reduced mortality and CVD events across all risk groups amongst type 2 diabetics.

Limiting diabetes risk on LDL-lowering drugs: statin risk is modest, alternatives exist
Review explaining that statins modestly increase new-onset diabetes in a dose-dependent way, mostly in people with existing metabolic risk factors, and that cardiovascular benefit clearly outweighs this. It suggests statins mainly bring forward diagnosis in predisposed people, outlines mechanisms (beta-cell dysfunction, insulin resistance) and proposes ezetimibe, PCSK9 inhibitors and pitavastatin as options that limit glycemic harm.

